In a major step forward for women’s health, the FDA has approved the Teal Wand, the first at-home cervical cancer screening device in the U.S. Developed by Teal Health, the wand allows women to collect their own samples for HPV testing, the virus responsible for nearly all cervical cancer cases, without visiting a clinic.
Targeted at women aged 25 to 65, the Teal Wand matches the clinical accuracy of doctor-collected samples, detecting cervical precancer 96% of the time. The device is paired with a full telehealth experience, where users receive medical guidance, results, and follow-up support.
CEO Kara Egan, who co-founded the company as a working mom, highlighted the significance; «when we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day.»
Over 25% of U.S. women are behind on screenings, often due to time, discomfort, or limited access. Teal aims to close that gap with a product designed for convenience and trust. In trials, 94% of users preferred self-collection, and 86% said they’d be more likely to stay up to date if they could do it from home.
With FDA backing, Teal will begin rolling out kits in June, starting in California and expanding nationally. The company is partnering with insurers and offering flexible payments to make care more accessible for all.
Article written by Kathrin Folkendt
09/05/2025
Source:
Femtech Insider